Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: Comparison with quinpirole and apomorphine

Psychopharmacology

Volumn 124, Issue 3, 1996, Pages 231-240

  Depoortere, R ^a   Perrault, Gh ^a   Sanger, D J ^a  

^a SANOFI   (France)

Author keywords

7 OH DPAT; Apomorphine; D3 receptors; Dopamine; Locomotor activity; Progressive ratio; Quinpirole; Rat; Self stimulation; Stereotypies

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; APOMORPHINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; QUINPIROLE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FOOD; INSTRUMENTAL CONDITIONING; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SELF STIMULATION; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION; VENTRAL TEGMENTUM;

ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DOPAMINE AGONISTS; MALE; MOTOR ACTIVITY; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SELF ADMINISTRATION; STEREOTYPED BEHAVIOR; TETRAHYDRONAPHTHALENES;

EID: 0029875739     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02246662     Document Type: Article

References (60)

1. 3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol 260: 177-181
2. 3 subtypes. Brain Res 649:95-110
3. Arnt J, Hyttel J, Perregaard J (1987) Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur J Pharmacol 133:137-145
4. 3 receptors. Eur J Pharmacol 239:269-270
5. Booth RG, Baldessarini RJ, Marsh E, Owens CE (1994) Actions of (±)-7-hydroxy-N,N-dipropylaminotetralin (7-OH-DPAT) on dopamine synthesis in limbic and extrapyramidal regions of rat brain. Brain Res 662:283-288
6. 2 receptor mRNA. Brain Res 564: 203-219
7. Caine SB, Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260: 1814-1816
8. Caine SB, Koob GF (1995) Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose-effect function to the left under different schedules in the rat. Behav Pharmacol 6:333-347
9. Costall B, Naylor RJ, Cannon JG, Lee T (1977) Differentiation of the dopamine mechanisms mediating stereotyped behaviour and hyperactivity in the nucleus accumbens and caudate-putamen. J Pharm Pharmacol 29:337-342
10. Daly SA, Waddington JL (1993) Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology 32:509-510
11. 3 receptor ligand. Eur J Pharmacol 249:R9-R10
12. De Fonseca FR, Rubio P, Martin-Calderon JL, Caine SB, Koob GF, Navarro M (1995) The dopamine receptor agonist 7-OH-DPAT modulates the acquisition and expression of morphine-induced place preference. Eur J Pharmacol 274:47-55
13. Dews PB, Wenger GR (1977) Rate-dependency of the behavioral effects of amphetamine. In: Thompson T, Dews PB (eds) Advances in behavioral pharmacology, vol. 1. Academic, New York, pp 167-227
14. Di Chiara G, Porceddu ML, Vargiu L, Argiolas A, Gessa GL (1976) Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 264:564-567
15. Eilam D, Szechtman H (1989) Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161: 151-157
16. Feenstra MGP, Sumners C, Goedemoed JH, de Vries JB, Rollema H, Horn AS (1983) A comparison of the potencies of various dopamine receptor agonists in models for pre- and postsynaptic receptor activity. Naunyn-Schmiedeberg's Arch Pharmacol 324:108-115
17. Fibiger HC, Phillips AG (1988) Mesocorticolimbic dopamine systems and reward. Ann NY Acad Sci 537:206-215
18. Gallistel CR, Karras D (1984) Pimozide and amphetamine have opposing effects on the reward summation function. Pharmacol Biochem Behav 20:73-77
19. Gallistel CR, Gomita Y, Yadin E, Campbell KA (1985) Fore brain origins and terminations of the medial forebrain bundle metabolically activated by rewarding stimulation or by reward-blocking doses of pimozide. J Neurosci 5[5]: 1246-1261
20. 3 agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum. Brain Res 681:1-7
21. 3 receptors. Eur J Pharmacol 272:R1-R3
22. Herberg LJ, Stephens DN, Franklin KBJ (1976) Catecholamines and self-stimulation: evidence suggesting a reinforcing role for noradrenaline and a motivating role for dopamine. Pharmacol Biochem Behav 4:575-582
23. Hernandez L, Hoebel BG (1988) Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life Sci 42:1705-1711
24. 3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res 648:222-228
25. 3 receptors in the islands of Calleja of the rat using quantitative receptor autoradiography. Eur J Pharmacol 261: 179-183
26. Hodos W (1961) Progressive ratio as a measure of reward strength. Science 134:943-944
27. Kirby KN (1993) Advanced data analysis with SYSTAT. Van Nostrand Reinhold, New York
28. 3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci 5:145-153
29. 3 receptor mRNA and binding sites in human brain. Mol Brain Res 18:187-192
30. Leith NJ (1983) Effects of apomorphine on self-stimulation responding: does the drug mimic the current? Brain Res 277:129-136
31. 3H)hydroxy-N, N-di-n-propyl-2- aminotetralin. Proc Natl Acad Sci USA 89:8155-8159
32. 3 receptor agonist 7-OH-DPAT: lack of mesolimbic selectivity. Eur J Pharmacol 264:269-278
33. Lynch MR, Wise RA (1985) Relative effectiveness of pimozide, haloperidol and trifluoperazine on self-stimulation rate-intensity functions. Pharmacol Biochem Behav 23:777-780
34. 3-selective receptor ligand. Drug Dev Res 30:257-259
35. 3-selective receptor ligand. Pharmacol Biochem Behav 48:531-533
36. 3 receptor expressed in transfected cell lines. Eur J Pharmacol [Mol Pharmacol Sec] 266:79-85
37. Mallet PE, Beninger RJ (1994) 7-OH-DPAT produces place conditioning in rats. Eur J Pharmacol 261:R5-R6
38. 3 receptors. Eur J Pharmacol 249:R5-R6
39. Mulder TB, de Vries JB, Dijkstra D, Wiechers JW, Grol CJ, Horn AS (1987) Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N, N-dipropyl-7-hydroxy-2-aminotetralin. Naunyn Schmiedeberg's Arch Pharmacol 336: 494-501
40. 125I)epidepride. Eur J Pharmacol 227:443-445
41. Nakajima S, O'Regan NB (1991) The effects of dopaminergic agonists and antagonists on the frequency-response function for hypothalamic self-stimulation in the rat. Pharmacol Biochem Behav 39:465-468
42. 2 dopamine receptors in the modulation of the reinforcing effect of brain stimulation. Behav Neurosci 107:161-165
43. 3 receptors in rat brain. Eur J Pharmacol 234:269-272
44. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, New York
45. Poncelet M, Chermat R, Soubrie P, Simon P (1983) The progressive ratio schedule as a model for studying the psychomotor stimulant activity of drugs in the rat. Psychopharmacology 80: 184-189
46. Sahakian BJ, Koob GF (1978) The relationship between pipradrol-induced responding for electrical brain stimulation, stereotyped behaviour and locomotor activity. Neuropharmacology 17: 363-366
47. 3 receptors and σ sites in the bovine caudate nucleus. Eur J Pharmacol 242:R1-R2
48. Seeman P, Van Tol HHM (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15:264-270
49. 3) as a target for neuroleptics. Nature 347:146-151
50. 3 dopamine receptor. Arzneimittelforschung 42:224-230
51. Stahle L, Ungerstedt U (1986) Effects of neuroleptic drugs on the inhibition of exploratory behaviour induced by a low dose of apomorphine: implications for the identity of dopamine receptors. Pharmacol Biochem Behav 25:473-480
52. Starr MS, Starr BS (1989) Behavioural synergism between the dopamine agonists SKF 38393 and LY 171555 in dopamine-depleted mice: antagonism by sulpiride reveals only stimulant postsynaptic D-2 receptors. Pharmacol Biochem Behav 33: 41-44
53. Stellar JR, Rice MB (1989) Pharmacological basis of intracranial self-stimulation reward. In: JM Liebman, SJ Cooper (eds) The neuropharmacological basis of reward. Oxford University Press, Oxford p 14-65
54. 3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm [Gen Sect] 95:71-74
55. 3 receptors. Eur J Pharmacol 263:235-243
56. 3 receptors inhibit dopamine release. J Pharmacol Exp Ther 270: 475-479
57. Timmerman W, Tepper PG, Dijkstra D, Stoelwinder H, Grol CJ, Westerink BHC, Horn AS (1991) Enantiomers of monohydroxy-2-aminotetralin derivatives and their activity at dopamine autoreceptors as studied by brain dialysis. Eur J Pharmacol 199:145-151
58. 2-adrenoceptor agonist selectivity of mono- and dihydroxy-2-N,N-di-n-propylaminotetralins. Eur J Pharmacol 97:55-65
59. Tsuruta K, Frey EA, Grewe CW, Cote TE, Eskay RL, Kebabian JW (1981) Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor. Nature 292:463-465
60. Van den Buuse M (1993) Effects of 7-hydroxy-N, N-di-n-propylaminotetralin on behaviour and blood pressure of spontaneously hypertensive rats. Eur J Pharmacol 243:169-177